The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.

Autor: Lawson H; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Holt-Martyn JP; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Dembitz V; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Physiology and Immunology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia., Kabayama Y; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Wang LM; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Bellani A; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Atwal S; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Saffoon N; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Durko J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., van de Lagemaat LN; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., De Pace AL; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Tumber A; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Corner T; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Salah E; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Arndt C; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Brewitz L; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Bowen M; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Dubusse L; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., George D; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Allen L; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Guitart AV; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.; Université de Bordeaux, Institut National de la Santé et de la Recherche Médicale INSERM U1035, Bordeaux, France., Fung TK; Leukemia and Stem Cell Biology Group, Comprehensive Cancer Centre, King's College London, London, UK.; Department of Haematological Medicine, King's College Hospital, King's College London, London, UK., So CWE; Leukemia and Stem Cell Biology Group, Comprehensive Cancer Centre, King's College London, London, UK.; Department of Haematological Medicine, King's College Hospital, King's College London, London, UK., Schwaller J; University Children's Hospital Basel (UKBB), Department of Biomedicine, University of Basel, Basel, Switzerland., Gallipoli P; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., O'Carroll D; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Schofield CJ; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK. christopher.schofield@chem.ox.ac.uk., Kranc KR; The Institute of Cancer Research, London, UK. kamil.kranc@icr.ac.uk.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. kamil.kranc@icr.ac.uk.

Publikováno v: Nature cancer [Nat Cancer] 2024 Jun; Vol. 5 (6), pp. 916-937. Date of Electronic Publication: 2024 Apr 18.

CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantation.

Autor: Lawson H; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., van de Lagemaat LN; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Barile M; Department of Haematology, Wellcome and Medical Research Council Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AW, UK., Tavosanis A; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Durko J; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Villacreces A; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Bellani A; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Mapperley C; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Georges E; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Martins-Costa C; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Sepulveda C; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Allen L; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Campos J; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Campbell KJ; CRUK Beatson Institute, Glasgow, UK., O'Carroll D; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Göttgens B; Department of Haematology, Wellcome and Medical Research Council Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AW, UK., Cory S; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Rodrigues NP; European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff CF24 4HQ, UK., Guitart AV; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Université de Bordeaux, Institut National de la Santé et de la Recherche Médicale INSERM U1035, 33000 Bordeaux, France. Electronic address: amelie.guitart@u-bordeaux.fr., Kranc KR; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Electronic address: kamil.kranc@qmul.ac.uk.

Publikováno v: Stem cell reports [Stem Cell Reports] 2021 Nov 09; Vol. 16 (11), pp. 2784-2797. Date of Electronic Publication: 2021 Oct 28.

α-Tocopherol Attenuates Oxidative Phosphorylation of CD34 ⁺ Cells, Enhances Their G0 Phase Fraction and Promotes Hematopoietic Stem and Primitive Progenitor Cell Maintenance.

Autor: Rodriguez L; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Duchez P; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Touya N; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Debeissat C; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Guitart AV; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Pasquet JM; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Vlaski-Lafarge M; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Brunet de la Grange P; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France., Ivanovic Z; Etablissement Français du Sang Nouvelle Aquitaine, Place Amélie Raba Léon, CS22010, CEDEX, 33075 Bordeaux, France.; Inserm Bordeaux UMR 1035, 33000 Bordeaux, France.; Université de Bordeaux, 33000 Bordeaux, France.

Publikováno v: Biomolecules [Biomolecules] 2021 Apr 10; Vol. 11 (4). Date of Electronic Publication: 2021 Apr 10.

Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.

Autor: Mansier O; Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France.; Laboratoire d'Hématologie, CHU de Bordeaux, Pessac, France., Kilani B; Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France., Guitart AV; Biothérapie des Maladies Génétiques Inflammatoires et Cancers, University of Bordeaux, INSERM, UMR1035, Bordeaux, France., Guy A; Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France., Gourdou-Latyszenok V; Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France., Marty C; University of Paris-Saclay, INSERM UMR1170, Gustave Roussy, Villejuif, France; and., Parrens M; Laboratoire d'Anatomopathologie, CHU de Bordeaux, Pessac, France., Plo I; University of Paris-Saclay, INSERM UMR1170, Gustave Roussy, Villejuif, France; and., Vainchenker W; University of Paris-Saclay, INSERM UMR1170, Gustave Roussy, Villejuif, France; and., James C; Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France.; Laboratoire d'Hématologie, CHU de Bordeaux, Pessac, France.

Publikováno v: Blood [Blood] 2019 Dec 26; Vol. 134 (26), pp. 2383-2387.

Targeting the RNA m ⁶ A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.

Autor: Paris J; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Morgan M; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK; Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK., Campos J; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Spencer GJ; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4GJ, UK., Shmakova A; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Ivanova I; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK., Mapperley C; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Lawson H; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Wotherspoon DA; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Sepulveda C; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Vukovic M; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Allen L; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Sarapuu A; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Tavosanis A; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Guitart AV; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Villacreces A; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK., Much C; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK., Choe J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Azar A; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., van de Lagemaat LN; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK., Vernimmen D; Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK., Nehme A; Université de Tours, CNRS, LNOx ERL 7001, Tours, France., Mazurier F; Université de Tours, CNRS, LNOx ERL 7001, Tours, France., Somervaille TCP; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4GJ, UK., Gregory RI; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., O'Carroll D; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH16 4UU, UK; Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK. Electronic address: donal.ocarroll@ed.ac.uk., Kranc KR; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Electronic address: kamil.kranc@qmul.ac.uk.

Publikováno v: Cell stem cell [Cell Stem Cell] 2019 Jul 03; Vol. 25 (1), pp. 137-148.e6. Date of Electronic Publication: 2019 Apr 25.